Alvotech (NASDAQ: ALVOW) Stock Competitors & Peer Comparison
See ALVOW's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ALVOW and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ALVOW | $0.37 | +19.36% | 3B | 46.65 | $0.01 | N/A |
| TAK | $18.91 | -0.73% | 60.2B | 13.60 | $1.39 | +3.32% |
| TEVA | $38.98 | -0.54% | 45.4B | 13.31 | $2.93 | N/A |
| HLN | $9.28 | -0.85% | 40.9B | 17.32 | $0.54 | +2.13% |
| ZTS | $71.40 | -2.22% | 30B | 10.86 | $6.58 | +2.89% |
| VTRS | $16.95 | -1.05% | 19.7B | 6.73 | $2.52 | +2.82% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.42 | -1.41% | 11.2B | 21.15 | $1.06 | N/A |
| RDY | $12.19 | +0.00% | 10.2B | 19.99 | $0.61 | +0.68% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
ALVOW vs TAK Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, TAK has a market cap of 60.2B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while TAK trades at $18.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas TAK's P/E ratio is 13.60. In terms of profitability, ALVOW's ROE is +0.77%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ALVOW is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
ALVOW vs TEVA Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, TEVA has a market cap of 45.4B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while TEVA trades at $38.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas TEVA's P/E ratio is 13.31. In terms of profitability, ALVOW's ROE is +0.77%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, ALVOW is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check TEVA's competition here
Haleon plc (NYSE: HLN)
ALVOW vs HLN Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, HLN has a market cap of 40.9B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while HLN trades at $9.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas HLN's P/E ratio is 17.32. In terms of profitability, ALVOW's ROE is +0.77%, compared to HLN's ROE of +0.17%. Regarding short-term risk, ALVOW is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
ALVOW vs ZTS Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, ZTS has a market cap of 30B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while ZTS trades at $71.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas ZTS's P/E ratio is 10.86. In terms of profitability, ALVOW's ROE is +0.77%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, ALVOW is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
ALVOW vs VTRS Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, VTRS has a market cap of 19.7B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while VTRS trades at $16.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas VTRS's P/E ratio is 6.73. In terms of profitability, ALVOW's ROE is +0.77%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, ALVOW is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
ALVOW vs ITCI Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ALVOW's ROE is +0.77%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ALVOW is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
ALVOW vs CTLT Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ALVOW's ROE is +0.77%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ALVOW is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
ALVOW vs ELAN Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, ELAN has a market cap of 11.2B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while ELAN trades at $22.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas ELAN's P/E ratio is 21.15. In terms of profitability, ALVOW's ROE is +0.77%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, ALVOW is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
ALVOW vs RDY Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, RDY has a market cap of 10.2B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while RDY trades at $12.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas RDY's P/E ratio is 19.99. In terms of profitability, ALVOW's ROE is +0.77%, compared to RDY's ROE of +0.09%. Regarding short-term risk, ALVOW is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
ALVOW vs ALKS Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, ALKS has a market cap of 7.8B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while ALKS trades at $43.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas ALKS's P/E ratio is 49.17. In terms of profitability, ALVOW's ROE is +0.77%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, ALVOW is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
ALVOW vs LNTH Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while LNTH trades at $100.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas LNTH's P/E ratio is 16.90. In terms of profitability, ALVOW's ROE is +0.77%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ALVOW is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
ALVOW vs AMRX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, AMRX has a market cap of 5.8B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while AMRX trades at $18.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas AMRX's P/E ratio is 20.31. In terms of profitability, ALVOW's ROE is +0.77%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, ALVOW is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
ALVOW vs INDV Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, INDV has a market cap of 4.4B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while INDV trades at $34.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas INDV's P/E ratio is 9.56. In terms of profitability, ALVOW's ROE is +0.77%, compared to INDV's ROE of -2.16%. Regarding short-term risk, ALVOW is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check INDV's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
ALVOW vs RGC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, RGC has a market cap of 2.9B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while RGC trades at $5.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas RGC's P/E ratio is -407.75. In terms of profitability, ALVOW's ROE is +0.77%, compared to RGC's ROE of -2.32%. Regarding short-term risk, ALVOW is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check RGC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
ALVOW vs SUPN Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, SUPN has a market cap of 2.4B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while SUPN trades at $42.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas SUPN's P/E ratio is 13.73. In terms of profitability, ALVOW's ROE is +0.77%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, ALVOW is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check SUPN's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
ALVOW vs HCM Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, HCM has a market cap of 2.4B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while HCM trades at $13.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas HCM's P/E ratio is 5.12. In terms of profitability, ALVOW's ROE is +0.77%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ALVOW is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check HCM's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
ALVOW vs DCPH Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ALVOW's ROE is +0.77%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ALVOW is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
ALVOW vs AVDL Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ALVOW's ROE is +0.77%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, ALVOW is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check AVDL's competition here
Bausch Health Companies Inc. (NYSE: BHC)
ALVOW vs BHC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, BHC has a market cap of 2.1B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while BHC trades at $5.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas BHC's P/E ratio is 1.45. In terms of profitability, ALVOW's ROE is +0.77%, compared to BHC's ROE of +0.89%. Regarding short-term risk, ALVOW is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check BHC's competition here
Embecta Corp. (NASDAQ: EMBCV)
ALVOW vs EMBCV Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ALVOW's ROE is +0.77%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ALVOW is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check EMBCV's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
ALVOW vs TRLV Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, TRLV has a market cap of 1.9B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while TRLV trades at $11.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas TRLV's P/E ratio is -4.50. In terms of profitability, ALVOW's ROE is +0.77%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, ALVOW is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check TRLV's competition here
Perrigo Company plc (NYSE: PRGO)
ALVOW vs PRGO Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, PRGO has a market cap of 1.9B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while PRGO trades at $13.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas PRGO's P/E ratio is 5.44. In terms of profitability, ALVOW's ROE is +0.77%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, ALVOW is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check PRGO's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
ALVOW vs DVAX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ALVOW's ROE is +0.77%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ALVOW is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
ALVOW vs ALVO Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while ALVO trades at $5.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas ALVO's P/E ratio is -15.71. In terms of profitability, ALVOW's ROE is +0.77%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, ALVOW is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ALVO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
ALVOW vs ANIP Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while ANIP trades at $76.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas ANIP's P/E ratio is 9.26. In terms of profitability, ALVOW's ROE is +0.77%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, ALVOW is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
ALVOW vs TARO Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas TARO's P/E ratio is 30.05. In terms of profitability, ALVOW's ROE is +0.77%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ALVOW is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check TARO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
ALVOW vs ETON Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, ETON has a market cap of 1.5B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while ETON trades at $55.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas ETON's P/E ratio is 120.65. In terms of profitability, ALVOW's ROE is +0.77%, compared to ETON's ROE of +0.40%. Regarding short-term risk, ALVOW is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ETON's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
ALVOW vs PAHC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while PAHC trades at $34.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas PAHC's P/E ratio is 11.80. In terms of profitability, ALVOW's ROE is +0.77%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, ALVOW is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
ALVOW vs CRON Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while CRON trades at $3.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas CRON's P/E ratio is 31.81. In terms of profitability, ALVOW's ROE is +0.77%, compared to CRON's ROE of +0.06%. Regarding short-term risk, ALVOW is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check CRON's competition here
Harrow Health, Inc. (NASDAQ: HROW)
ALVOW vs HROW Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while HROW trades at $33.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas HROW's P/E ratio is -33.41. In terms of profitability, ALVOW's ROE is +0.77%, compared to HROW's ROE of -1.04%. Regarding short-term risk, ALVOW is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check HROW's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
ALVOW vs AMPH Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while AMPH trades at $23.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas AMPH's P/E ratio is 8.13. In terms of profitability, ALVOW's ROE is +0.77%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, ALVOW is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check AMPH's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
ALVOW vs PCRX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, PCRX has a market cap of 971.2M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while PCRX trades at $24.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas PCRX's P/E ratio is 9.50. In terms of profitability, ALVOW's ROE is +0.77%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, ALVOW is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
ALVOW vs PETQ Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ALVOW's ROE is +0.77%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ALVOW is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
ALVOW vs COLL Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, COLL has a market cap of 738.5M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while COLL trades at $22.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas COLL's P/E ratio is 2.86. In terms of profitability, ALVOW's ROE is +0.77%, compared to COLL's ROE of +0.16%. Regarding short-term risk, ALVOW is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
ALVOW vs IRWD Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, IRWD has a market cap of 717.7M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while IRWD trades at $4.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas IRWD's P/E ratio is 5.59. In terms of profitability, ALVOW's ROE is +0.77%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, ALVOW is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check IRWD's competition here
Glass House Brands Inc (NYSE: GLAS)
ALVOW vs GLAS Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, GLAS has a market cap of 614M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while GLAS trades at $7.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas GLAS's P/E ratio is -14.17. In terms of profitability, ALVOW's ROE is +0.77%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, ALVOW is more volatile compared to GLAS. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check GLAS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
ALVOW vs AQST Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, AQST has a market cap of 578.4M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while AQST trades at $4.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas AQST's P/E ratio is -7.09. In terms of profitability, ALVOW's ROE is +0.77%, compared to AQST's ROE of +2.44%. Regarding short-term risk, ALVOW is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check AQST's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
ALVOW vs BDSI Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ALVOW's ROE is +0.77%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ALVOW is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check BDSI's competition here
Evotec SE (NASDAQ: EVO)
ALVOW vs EVO Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, EVO has a market cap of 568.4M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while EVO trades at $1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas EVO's P/E ratio is -2.26. In terms of profitability, ALVOW's ROE is +0.77%, compared to EVO's ROE of -0.27%. Regarding short-term risk, ALVOW is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check EVO's competition here
Evolus, Inc. (NASDAQ: EOLS)
ALVOW vs EOLS Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, EOLS has a market cap of 517.6M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while EOLS trades at $7.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas EOLS's P/E ratio is -24.89. In terms of profitability, ALVOW's ROE is +0.77%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, ALVOW is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
ALVOW vs KMDA Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, KMDA has a market cap of 510.6M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while KMDA trades at $8.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas KMDA's P/E ratio is 23.29. In terms of profitability, ALVOW's ROE is +0.77%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ALVOW is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check KMDA's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
ALVOW vs TLRY Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, TLRY has a market cap of 446.2M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while TLRY trades at $3.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas TLRY's P/E ratio is -3.68. In terms of profitability, ALVOW's ROE is +0.77%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, ALVOW is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check TLRY's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
ALVOW vs TKNO Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, TKNO has a market cap of 417.7M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while TKNO trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas TKNO's P/E ratio is -25.13. In terms of profitability, ALVOW's ROE is +0.77%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ALVOW is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check TKNO's competition here
Canopy Growth Corporation (NASDAQ: CGC)
ALVOW vs CGC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, CGC has a market cap of 394.5M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while CGC trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas CGC's P/E ratio is -2.09. In terms of profitability, ALVOW's ROE is +0.77%, compared to CGC's ROE of -0.33%. Regarding short-term risk, ALVOW is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check CGC's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
ALVOW vs EBS Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, EBS has a market cap of 349.8M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while EBS trades at $6.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas EBS's P/E ratio is 4.71. In terms of profitability, ALVOW's ROE is +0.77%, compared to EBS's ROE of -0.36%. Regarding short-term risk, ALVOW is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
ALVOW vs ALIM Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ALVOW's ROE is +0.77%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ALVOW is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
ALVOW vs LNDC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ALVOW's ROE is +0.77%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, ALVOW is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
ALVOW vs ACB Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, ACB has a market cap of 239.7M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while ACB trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas ACB's P/E ratio is -2.79. In terms of profitability, ALVOW's ROE is +0.77%, compared to ACB's ROE of -0.21%. Regarding short-term risk, ALVOW is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ACB's competition here
Shineco, Inc. (NASDAQ: TYHT)
ALVOW vs TYHT Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ALVOW's ROE is +0.77%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ALVOW is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
ALVOW vs SIGA Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, SIGA has a market cap of 225.2M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while SIGA trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas SIGA's P/E ratio is 11.63. In terms of profitability, ALVOW's ROE is +0.77%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, ALVOW is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check SIGA's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
ALVOW vs CRDL Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, CRDL has a market cap of 216.1M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while CRDL trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas CRDL's P/E ratio is -7.47. In terms of profitability, ALVOW's ROE is +0.77%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, ALVOW is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check CRDL's competition here
Journey Medical Corporation (NASDAQ: DERM)
ALVOW vs DERM Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, DERM has a market cap of 201.2M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while DERM trades at $7.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas DERM's P/E ratio is -19.76. In terms of profitability, ALVOW's ROE is +0.77%, compared to DERM's ROE of -0.20%. Regarding short-term risk, ALVOW is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check DERM's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
ALVOW vs ORGO Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, ORGO has a market cap of 182.7M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while ORGO trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas ORGO's P/E ratio is 47.33. In terms of profitability, ALVOW's ROE is +0.77%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, ALVOW is more volatile compared to ORGO. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ORGO's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
ALVOW vs REPH Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas REPH's P/E ratio is -8.04. In terms of profitability, ALVOW's ROE is +0.77%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ALVOW is more volatile compared to REPH. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check REPH's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
ALVOW vs LFCR Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, LFCR has a market cap of 167.3M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while LFCR trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas LFCR's P/E ratio is -4.17. In terms of profitability, ALVOW's ROE is +0.77%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, ALVOW is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check LFCR's competition here
Theratechnologies Inc. (NASDAQ: THTX)
ALVOW vs THTX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas THTX's P/E ratio is -28.83. In terms of profitability, ALVOW's ROE is +0.77%, compared to THTX's ROE of +0.36%. Regarding short-term risk, ALVOW is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
ALVOW vs ASRT Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas ASRT's P/E ratio is -7.10. In terms of profitability, ALVOW's ROE is +0.77%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, ALVOW is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ASRT's competition here
Organigram Global Inc. (NASDAQ: OGI)
ALVOW vs OGI Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, OGI has a market cap of 147.8M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while OGI trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas OGI's P/E ratio is 2.36. In terms of profitability, ALVOW's ROE is +0.77%, compared to OGI's ROE of +0.21%. Regarding short-term risk, ALVOW is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check OGI's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
ALVOW vs SCTL Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ALVOW's ROE is +0.77%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ALVOW is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check SCTL's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
ALVOW vs CPIX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, CPIX has a market cap of 109.7M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while CPIX trades at $7.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas CPIX's P/E ratio is -18.30. In terms of profitability, ALVOW's ROE is +0.77%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, ALVOW is more volatile compared to CPIX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check CPIX's competition here
Procaps Group S.A. (NASDAQ: PROC)
ALVOW vs PROC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas PROC's P/E ratio is 1.53. In terms of profitability, ALVOW's ROE is +0.77%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ALVOW is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check PROC's competition here
BGM Group Ltd. (NASDAQ: BGM)
ALVOW vs BGM Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, BGM has a market cap of 98.5M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while BGM trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas BGM's P/E ratio is -0.89. In terms of profitability, ALVOW's ROE is +0.77%, compared to BGM's ROE of -0.05%. Regarding short-term risk, ALVOW is more volatile compared to BGM. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check BGM's competition here
OptiNose, Inc. (NASDAQ: OPTN)
ALVOW vs OPTN Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ALVOW's ROE is +0.77%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ALVOW is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
ALVOW vs ZOM Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ALVOW's ROE is +0.77%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, ALVOW is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
ALVOW vs GRVI Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ALVOW's ROE is +0.77%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, ALVOW is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
ALVOW vs ZYNE Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ALVOW's ROE is +0.77%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ALVOW is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
ALVOW vs SSIC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ALVOW's ROE is +0.77%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ALVOW is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check SSIC's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
ALVOW vs ZYBT Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, ZYBT has a market cap of 64.9M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while ZYBT trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas ZYBT's P/E ratio is -6.23. In terms of profitability, ALVOW's ROE is +0.77%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, ALVOW is more volatile compared to ZYBT. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ZYBT's competition here
InterCure Ltd. (NASDAQ: INCR)
ALVOW vs INCR Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, INCR has a market cap of 62.8M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while INCR trades at $5.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas INCR's P/E ratio is -12.23. In terms of profitability, ALVOW's ROE is +0.77%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ALVOW is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check INCR's competition here
The Valens Company Inc. (NASDAQ: VLNS)
ALVOW vs VLNS Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ALVOW's ROE is +0.77%, compared to VLNS's ROE of N/A. Regarding short-term risk, ALVOW is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check VLNS's competition here
Talphera, Inc. (NASDAQ: TLPH)
ALVOW vs TLPH Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, TLPH has a market cap of 60.2M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while TLPH trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas TLPH's P/E ratio is -3.74. In terms of profitability, ALVOW's ROE is +0.77%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, ALVOW is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check TLPH's competition here
DURECT Corporation (NASDAQ: DRRX)
ALVOW vs DRRX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ALVOW's ROE is +0.77%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, ALVOW is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
ALVOW vs JUPW Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ALVOW's ROE is +0.77%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, ALVOW is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
ALVOW vs QLI Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas QLI's P/E ratio is -4.92. In terms of profitability, ALVOW's ROE is +0.77%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ALVOW is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check QLI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
ALVOW vs RMTI Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, RMTI has a market cap of 31.8M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while RMTI trades at $8.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas RMTI's P/E ratio is -6.02. In terms of profitability, ALVOW's ROE is +0.77%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, ALVOW is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
ALVOW vs HEXO Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ALVOW's ROE is +0.77%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ALVOW is more volatile compared to HEXO. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check HEXO's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
ALVOW vs CPHI Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, CPHI has a market cap of 28.8M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while CPHI trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas CPHI's P/E ratio is -1.65. In terms of profitability, ALVOW's ROE is +0.77%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, ALVOW is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check CPHI's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
ALVOW vs TXMD Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, TXMD has a market cap of 25.3M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while TXMD trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas TXMD's P/E ratio is 111.56. In terms of profitability, ALVOW's ROE is +0.77%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, ALVOW is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
ALVOW vs CYTH Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ALVOW's ROE is +0.77%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ALVOW is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check CYTH's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
ALVOW vs AYTU Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, AYTU has a market cap of 22.8M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while AYTU trades at $2.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas AYTU's P/E ratio is -1.10. In terms of profitability, ALVOW's ROE is +0.77%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, ALVOW is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check AYTU's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
ALVOW vs EVOK Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ALVOW's ROE is +0.77%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, ALVOW is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
ALVOW vs OPTH Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, OPTH has a market cap of 16.1M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while OPTH trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas OPTH's P/E ratio is -18.26. In terms of profitability, ALVOW's ROE is +0.77%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, ALVOW is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
ALVOW vs ACRX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ALVOW's ROE is +0.77%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, ALVOW is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
ALVOW vs CABR Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, CABR has a market cap of 12.7M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while CABR trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas CABR's P/E ratio is -2.50. In terms of profitability, ALVOW's ROE is +0.77%, compared to CABR's ROE of -3.86%. Regarding short-term risk, ALVOW is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
ALVOW vs AGRX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ALVOW's ROE is +0.77%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ALVOW is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
ALVOW vs NLTX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ALVOW's ROE is +0.77%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, ALVOW is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
ALVOW vs LCI Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas LCI's P/E ratio is -0.04. In terms of profitability, ALVOW's ROE is +0.77%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ALVOW is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
ALVOW vs ADMP Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ALVOW's ROE is +0.77%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ALVOW is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ADMP's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
ALVOW vs GELS Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, GELS has a market cap of 5.2M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while GELS trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas GELS's P/E ratio is -1.12. In terms of profitability, ALVOW's ROE is +0.77%, compared to GELS's ROE of -0.25%. Regarding short-term risk, ALVOW is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check GELS's competition here
cbdMD, Inc. (AMEX: YCBD)
ALVOW vs YCBD Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, YCBD has a market cap of 4.7M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while YCBD trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas YCBD's P/E ratio is -1.11. In terms of profitability, ALVOW's ROE is +0.77%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ALVOW is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check YCBD's competition here
Mallinckrodt plc (AMEX: MNK)
ALVOW vs MNK Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas MNK's P/E ratio is -0.44. In terms of profitability, ALVOW's ROE is +0.77%, compared to MNK's ROE of -0.36%. Regarding short-term risk, ALVOW is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
ALVOW vs FLGC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ALVOW's ROE is +0.77%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ALVOW is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
ALVOW vs UPC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, UPC has a market cap of 3M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while UPC trades at $4.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas UPC's P/E ratio is -0.60. In terms of profitability, ALVOW's ROE is +0.77%, compared to UPC's ROE of -0.03%. Regarding short-term risk, ALVOW is more volatile compared to UPC. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check UPC's competition here
IM Cannabis Corp. (NASDAQ: IMCC)
ALVOW vs IMCC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, IMCC has a market cap of 2.6M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while IMCC trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas IMCC's P/E ratio is -2.42. In terms of profitability, ALVOW's ROE is +0.77%, compared to IMCC's ROE of +8.42%. Regarding short-term risk, ALVOW is less volatile compared to IMCC. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check IMCC's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
ALVOW vs PLXP Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ALVOW's ROE is +0.77%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ALVOW is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check PLXP's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
ALVOW vs INM Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, INM has a market cap of 2.5M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while INM trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas INM's P/E ratio is -0.25. In terms of profitability, ALVOW's ROE is +0.77%, compared to INM's ROE of -1.35%. Regarding short-term risk, ALVOW is more volatile compared to INM. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check INM's competition here
Athenex, Inc. (NASDAQ: ATNX)
ALVOW vs ATNX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ALVOW's ROE is +0.77%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ALVOW is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
ALVOW vs SNOA Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while SNOA trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas SNOA's P/E ratio is -1.08. In terms of profitability, ALVOW's ROE is +0.77%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, ALVOW is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check SNOA's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
ALVOW vs SBFM Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3B. In comparison, SBFM has a market cap of 2.1M. Regarding current trading prices, ALVOW is priced at $0.37 on the NASDAQ, while SBFM trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 46.65, whereas SBFM's P/E ratio is -0.15. In terms of profitability, ALVOW's ROE is +0.77%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, ALVOW is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check SBFM's competition here